Respirerx Pharmaceuticals Inc   (RSPI)
Other Ticker:  
Price: $0.0008 $0.00 14.286%
Day's High: $0.0008 Week Perf: -11.11 %
Day's Low: $ 0.00 30 Day Perf: -11.11 %
Volume (M): 4,473 52 Wk High: $ 0.01
Volume (M$): $ 4 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00

 Market Capitalization (Millions $) 0
 Shares Outstanding (Millions) 168
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -3
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Respirerx Pharmaceuticals Inc
Respirerx Pharmaceuticals Inc is a pharmaceutical company that specializes in the development and commercialization of respiratory and CNS therapeutics. The company focuses on the treatment of diseases such as chronic obstructive pulmonary disease (COPD) and asthma. Respirerx Pharmaceuticals aims to provide innovative and effective therapies that improve the lives of patients suffering from these conditions.

   Company Address: 126 Valley Road Glen Rock 7452 NJ
   Company Phone Number: 444-4947   Stock Exchange / Ticker: RSPI


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Respirerx Pharmaceuticals Inc

Respirerx Pharmaceuticals Inc defies expectations with brilliant policy implementation, emerging as major player in Pharmaceutical Preparations industry

The stock market is buzzing with exciting updates as the April to June 30, 2023 reporting season unfolds. Many entities have already announced their earnings, including several major players in the thriving Major Pharmaceutical Preparations industry. Among these entities is Respirerx Pharmaceuticals Inc (RSPI), which recently reported an operating shortfall of $-0.465859 million for the financial interval ending June 30, 2023.
Analyzing the financial performance of a company during a specific period provides valuable insights into its growth and potential. It paints a picture of how well an organization has fared within a given timeframe and allows investors to make informed decisions. The second quarter of 2023 has proven to be a remarkable one for RSPI, showcasing a brilliant policy implemented by its management.

Respirerx Pharmaceuticals Inc

Dramatic Upward Surge in Q1 2023 Favors Shareholders, as Major Pharma Outfit, Respirerx Pharmaceuticals Inc, Reveals Operating Deficit of Just $-0.390374 Million!

The Major Pharmaceutical Preparations sector is in trouble, and this has been reinforced by the recent analysis of the first quarter of 2023 numbers. The veteran experts from the industry have observed an operating deficit of a significant $-0.390374 million, which is a worrying sign. What is even more concerning is that there is still no sight of any revenue being mentioned in the financial reporting period from January to March 31, 2023. This indicates that the sector is struggling to generate any income, and this could spell disaster for the companies operating in this space.
The performance of the first quarter of 2022 is a perfect indication of the declining health of the industry. At that time, the operating deficit stood at an astounding $-0.616952 million. The fact that the situation has only marginally improved over the last year is a testament to the worsening state of the industry. This trend could spell the end for some of the companies operating in this space if things do not improve soon.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com